NCT02866747 2026-04-14
STERIMGLI
Institut Claudius Regaud
Phase 1/2 Completed
Clinical Trials
10 trialsNCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT04538742 2025-12-08
DB-07
AstraZeneca
Phase 1/2 Active not recruiting
NCT04521686 2025-06-27
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03991832 2024-07-18
SOLID
University Health Network, Toronto
Phase 2 Recruiting
NCT04610684 2024-03-13
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02793466 2023-09-22
Durvalumab in Pediatric and Adolescent Patients
Children's Hospital Los Angeles
Phase 1 Completed
NCT02336165 2022-10-12
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Ludwig Institute for Cancer Research
Phase 2 Completed
NCT02794883 2022-04-18
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Northwestern University
Phase 2 Completed
NCT04356222 2020-05-27
Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
Hebei Medical University
Phase 4 Unknown